CADTH Drug Portfolio Information Sessions
This annual session is an opportunity for all interested stakeholders to get the latest information about priority initiatives and process changes from CADTH’s pharmaceutical reviews portfolio. Updates on other relevant CADTH initiatives will also be provided. The session also includes an open forum, where attendees can direct questions to CADTH President and CEO Dr. Brian O’Rourke, and other senior staff at CADTH.
Видео CADTH Drug Portfolio Information Sessions канала Canada’s Drug Agency
Видео CADTH Drug Portfolio Information Sessions канала Canada’s Drug Agency
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
There's Always Evidence (Part 2) - Beyond RCTs: The Many Benefits of Observational Studies
CADTH in Conversation with…. Professor Gillian Leng CBE, Chief Executive of NICE
INFORMATION SESSION — Introducing CADTH’s New Post-Market Drug Evaluation Program
2017 CADTH Symposium: Janet Knox
2017 CADTH Symposium: Robyn Lim
CADTH Drug Reimbursement Reviews
How CADTH Expert Committees Deliberate
2017 CADTH Symposium: Ken Milne
Release of the CADTH Health Economic Guidelines
Recommendation Mapping: A New Approach to Digitizing and Presenting Living Guidelines
There's Always Evidence Part 3 - Observational Studies: A Deeper Dive
Dr. Wendy Ungar, Recipient of the 2020 Dr. Jill M. Sanders Award of Excellence in HTA
Impact of Zika Virus-Associated Neurological Disorders on Health-Related Quality of Life
2018 CADTH Symposium — Oral Presentations: Opioids
2018 CADTH Symposium: Dr. Tony Fields, the 2018 Dr. Jill M. Sanders Award Recipient
Implementing Health Technology–Related Decisions
Toward Standardized Structured Reporting for the Management of Multiple Myeloma in Alberta
There’s Always Evidence: Part 1
COVID-19 and the Surge in Virtual Care: Lessons Learned and Challenges to Come
Non-Pharmacological Interventions for Chronic Non-Cancer Pain: Acupuncture
Community-Based Aerosol Transmission Of COVID-19 and HVAC Systems